Adamopoulos Dimitrios A, Pappa Athina, Billa Evangelia, Nicopoulou Stamatina, Koukkou Eftychia, Michopoulos John
Department of Endocrinology, Elena Venizelou Hospital, Athens, Greece.
Fertil Steril. 2003 Oct;80(4):914-20. doi: 10.1016/s0015-0282(03)01123-3.
To assess the effect of treatment with a combination of the antiestrogen tamoxifen citrate and the androgen testosterone undecanoate on sperm variables and pregnancy incidence in men with idiopathic oligozoospermia and couple subfertility.
Prospective, randomized, placebo-controlled trial.
Clinical research in a tertiary care academic hospital.
PATIENT(S): Two hundred twelve men with idiopathic oligozoospermia and 82 normozoospermic men with female factor subfertility.
INTERVENTION(S): Oligozoospermic patients were randomly assigned to two treatment groups with tamoxifen citrate, 20 mg/d, and testosterone undecanoate, 120 mg/d (n = 106) or placebo treatment (n = 106) for 6 months. Normozoospermic men were followed for the same period. Couple counseling was part of the intervention in all groups.
MAIN OUTCOME MEASURE(S): Pregnancy incidence and sperm characteristics after 3 and 6 months on medication and 3 months after the end of the trial.
RESULT(S): In the active treatment group, total sperm count (median [25th, 75th percentile], 27.1 x 10(6) cells/mL [9.4, 54.0 x 10(6) cells/mL] at baseline and 61.5 x 10(6) cells/mL [28.2, 119.6 x 10(6) cells/mL] at 6 months), progressive motility (mean [+/-SD], 29.7% +/- 12.0% at baseline and 41.6% +/- 13.1% at 6 months), and normal morphology (mean, 41.2% +/- 14.0% at baseline and 56.6% +/- 11.5% at 6 months) were noted. No marked changes were observed in placebo recipients or normozoospermic men. The incidence of spontaneous pregnancy was 33.9% in the active treatment group and 10.3% in the placebo group (36 vs. 11 pregnancies), with a relative risk of 3.195 (95% CI, 2.615 to 3.765).
CONCLUSION(S): Treatment with tamoxifen citrate and testosterone undecanoate improved sperm variables and led to a higher incidence of pregnancy in couples with subfertility related to idiopathic oligozoospermia.
评估抗雌激素枸橼酸他莫昔芬与雄激素十一酸睾酮联合治疗对特发性少精子症男性患者精子参数及不育夫妇妊娠率的影响。
前瞻性、随机、安慰剂对照试验。
三级医疗学术医院的临床研究。
212例特发性少精子症男性患者以及82例因女性因素导致不育的正常精子密度男性。
少精子症患者被随机分为两组,一组接受枸橼酸他莫昔芬20mg/d及十一酸睾酮120mg/d治疗(n = 106),另一组接受安慰剂治疗(n = 106),为期6个月。正常精子密度男性随访相同时间。所有组均将夫妇咨询作为干预措施的一部分。
用药3个月和6个月时以及试验结束后3个月时的妊娠率和精子特征。
在积极治疗组中,观察到总精子计数(中位数[第25、75百分位数],基线时为27.1×10⁶个细胞/mL[9.4,54.0×10⁶个细胞/mL],6个月时为61.5×10⁶个细胞/mL[28.2,119.6×10⁶个细胞/mL])、前向运动率(平均值[±标准差],基线时为29.7%±12.0%,6个月时为41.6%±13.1%)和正常形态率(平均值:基线时为41.2%±14.0%,6个月时为56.6%±11.5%)均有所改善。安慰剂组患者及正常精子密度男性未观察到明显变化。积极治疗组自然妊娠率为33.9%,安慰剂组为10.3%(分别为36例和11例妊娠),相对风险为3.195(95%CI,2.615至3.765)。
枸橼酸他莫昔芬与十一酸睾酮联合治疗可改善精子参数,并使与特发性少精子症相关的不育夫妇妊娠率升高。